Non-canonical roles for growth factors in the nucleus have been previously described, but their mechanism of action and biological roles remain enigmatic. Platelet-derived growth factor B (PDGFB) can drive formation of low-grade glioma and here we show that it localizes to the nucleus of human glioma cells where it binds chromatin to preserve genome stability and cell lineage. Failure of PDGFB to localize to the nucleus leads to chromosomal abnormalities, aberrant heterochromatin architecture and accelerated tumorigenesis. Furthermore, nuclear localization of PDGFB is reliant upon the expression levels and mutation status of isocitrate dehydrogenase (IDH). Unexpectedly, we identified macrophages as the predominant source of PDGFB in human, finding that immune-derived PDGFB can localize to the nucleus of glioma cells. Collectively, these studies show that immune derived PDGFB enters the nucleus of glioma cells to maintain genomic stability, while identifying a new mechanism by which IDH mutations promote gliomagenesis.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11888161 | PMC |
| http://dx.doi.org/10.1101/2025.02.20.639365 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Role of TIM-3 in Glioblastoma Progression.
Cells
February 2025
Fiona Elsey Cancer Research Institute, Ballarat, VIC 3350, Australia.
Several immunoregulatory or immune checkpoint receptors including T cell immunoglobulin and mucin domain 3 (TIM-3) have been implicated in glioblastoma progression. Rigorous investigation over the last decade has elucidated TIM-3 as a key player in inhibiting immune cell activation and several key associated molecules have been identified both upstream and downstream that mediate immune cell dysfunction mechanistically. However, despite several reviews being published on other immune checkpoint molecules such as PD-1 and CTLA-4 in the glioblastoma setting, no such extensive review exists that specifically focuses on the role of TIM-3 in glioblastoma progression and immunosuppression.
View Article and Find Full Text PDFIndividual Brain Tumor Invasion Mapping Based on Diffusion Kurtosis Imaging.
Sovrem Tekhnologii Med
March 2025
MD, DSc, Professor, Academician of the Russian Academy of Sciences, Director; N.N. Burdenko National Medical Research Center of Neurosurgery of the Ministry of Health of the Russian Federation, 16, 4th Tverskaya-Yamskaya St., Moscow, 125047, Russia.
Unlabelled: is to develop and implement an algorithm for image analysis in brain tumors (glioblastoma and metastasis) based on diffusion kurtosis MRI images (DKI) for the assessment of anisotropic changes in brain tissues in the directions from the tumor to the intact (as shown by the standard MRI data) white matter, which will enable generating individual tumor invasion maps.
Materials And Methods: A healthy volunteer and two patients (one with glioblastoma and the other with a single metastasis of small cell lung cancer) were examined by DKI obtaining 12 parametric kurtosis maps for each participant.
Results: During the investigation, we have developed an algorithm of DKI analysis and plotting the profile of tissue parameters in the direction from the tumor towards the unaffected white matter according to the data of standard MRI.
Efficacy Evaluation of "Enhanced" Natural Killers with and Knockouts on Viability and Metabolic Status of 3D Glioblastoma Spheroid Cells in Patients.
Sovrem Tekhnologii Med
March 2025
MD, PhD, Senior Researcher, Laboratory of Cell Technologies; Federal Scientific and Clinical Center of the Federal Medical Biological Agency of Russia, 28 Orekhovy Blvd., Moscow, 115682, Russia; Head of the Laboratory of Solid Tumor Immunotherapy; Federal Center of Brain Research and Neurotechnologies of the Federal Medical Biological Agency of Russia, 1, Bldg. 10, Ostrovityanova St., Moscow, 117513, Russia; Senior Researcher, Laboratory of Molecular Regeneration Mechanisms; Engelhardt Institute of Molecular Biology of the Russian Academy of Sciences, 32 Vavilov St., Moscow, 119991, Russia.
Unlabelled: One of the alternative approaches to glioblastoma treatment is cellular immunotherapy based on natural killer cells (NK cells). To enhance their cytotoxic effect on tumor cells, new NK cell lines are being created using genetic engineering techniques. was to evaluate the impact efficacy of "enhanced" NK cells on early metabolic rearrangements and the viability of glioblastoma cells in a patient using a tumor spheroid model.
View Article and Find Full Text PDFMigration of Regulatory T Cells to the Peritumor Microenvironment of Experimental Glioblastoma.
Sovrem Tekhnologii Med
March 2025
MD, PhD, Head of the Laboratory of Solid Tumor Immunotherapy; Federal Center of Brain Research and Neurotechnologies of the Federal Medical Biological Agency of Russia, 1, Bldg. 10, Ostrovityanova St., Moscow, 117513, Russia; Senior Researcher, Laboratory of Cell Technologies; Federal Scientific and Clinical Center for Specialized Types of Medical Care and Medical Technologies of the Federal Medical Biological Agency of Russia, 28 Orekhovy Blvd., Moscow, 115682, Russia; Senior Researcher, Laboratory of Molecular Regeneration Mechanisms; Engelhardt Institute of Molecular Biology of the Russian Academy of Sciences, 32 Vavilov St., Moscow, 119991, Russia.
Unlabelled: Glioblastoma is the most aggressive primary brain tumor with poor prognosis characterized by resistance to standard treatments and immune evasion. Regulatory T lymphocytes (Tregs) play a key role in immune suppression in the tumor microenvironment and can be used as targets for malignant gliomas therapy. is to study migration of Tregs to the tumor site in the process of dynamic glioblastoma growth on the transgenic C57Bl/6-FoxP3-eGFP mouse line.
View Article and Find Full Text PDFLocoregional Infusion of EGFR806-CAR T Cells for Recurrent or Refractory Pediatric CNS Tumors: Results of the Completed BrainChild02 Phase 1 Clinical Trial.
Neuro Oncol
March 2025
Department of Pediatrics, Seattle Children's Hospital, University of Washington, Seattle Washington.
Background: Relapsed/refractory pediatric CNS tumors have a poor prognosis. EGFR is commonly overexpressed, but EGFRvIII mutations are uncommon. To target these tumors, we used chimeric antigen receptor (CAR) T cells with a binder based on mAb806 which recognizes ectopically expressed wild-type EGFR and EGFRvIII.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!